M&A Advisor for Radiology Practice Owners: 2026 Sell-Side Guide

By Christoph Totter, Managing Partner, CT Acquisitions. Last reviewed: July 2026.

Selecting an M&A advisor for a radiology practice in 2026 sits at the intersection of three pressures that no generalist broker can price correctly: continued Medicare Physician Fee Schedule reductions to imaging codes tracked by the Centers for Medicare and Medicaid Services, a still-active teleradiology consolidation wave led by platforms such as Radiology Partners and public operator RadNet, Inc. (NASDAQ: RDNT), and state-by-state corporate practice of medicine (CPOM) rules that shape whether a professional corporation can even be sold to a private-equity-backed MSO. This guide walks radiology practice owners through how the sell-side process actually runs for imaging groups, which buyers are currently active, and the specific questions that separate a specialist advisor from a generalist.

Executive summary

Radiology M&A activity in 2024 and 2025 remained concentrated among a small set of PE-backed and public consolidators, with Radiology Partners and RadNet reported as the two largest platforms per Becker’s Hospital Review imaging coverage . Medicare imaging reimbursement remained under pressure through the 2026 Physician Fee Schedule cycle, with cuts to CT, MRI, and interventional codes tracked in the Federal Register CMS docket and the American College of Radiology.

• Radiology M&A activity in 2024 and 2025 remained concentrated among a small set of PE-backed and public consolidators, with Radiology Partners and RadNet reported as the two largest platforms per Becker’s Hospital Review imaging coverage.
• Medicare imaging reimbursement remained under pressure through the 2026 Physician Fee Schedule cycle, with cuts to CT, MRI, and interventional codes tracked in the Federal Register CMS docket and the American College of Radiology (ACR) advocacy portal.
• The federal No Surprises Act continues to reshape out-of-network billing economics for hospital-based radiology contracts, per CMS No Surprises Act guidance.
• Hospital contract concentration is the single largest diligence flashpoint in radiology deals, per practitioner commentary published by the American College of Radiology.
• Radiology deal multiples are not publicly disclosed for private MSO transactions; any advisor quoting a “market multiple” without a specific source citation is quoting a category the seller cannot verify, and this guide keeps ranges conditional throughout.

Key findings

The radiology buyer universe would divide into three legible groups in 2026: PE-backed MSO platforms ( Radiology Partners , LucidHealth , US Radiology Specialists , Envision Radiology ), one public strategic ( RadNet, Inc. ), and hospital systems that continue insourcing outpatient imaging. Teleradiology capability, including night and subspecialty reads, would be treated as a value-driver rather than a peripheral service in advisor pitch materials, given the market position of.

1. The radiology buyer universe would divide into three legible groups in 2026: PE-backed MSO platforms (Radiology Partners, LucidHealth, US Radiology Specialists, Envision Radiology), one public strategic (RadNet, Inc.), and hospital systems that continue insourcing outpatient imaging.
2. Teleradiology capability, including night and subspecialty reads, would be treated as a value-driver rather than a peripheral service in advisor pitch materials, given the market position of vRad, a MEDNAX company and Radiology Partners’ teleradiology division.
3. Corporate practice of medicine restrictions vary meaningfully by state, per the American Medical Association CPOM overview, and the required MSO structure would drive both timeline and legal cost.
4. Hospital professional services agreements (PSAs) are the largest single revenue block for most groups, and a single-hospital PSA over 40% of revenue would compress multiples materially in buyer models.
5. The 2026 Medicare Physician Fee Schedule remained the reference dataset for professional-component reimbursement modeling and would appear in every diligence QoE.
6. Advanced imaging modality mix (MRI, PET/CT, interventional) drives EBITDA quality more than raw study volume, and a modality-weighted revenue analysis would appear in any specialist advisor’s CIM.
7. Valuation methodology in private radiology transactions would commonly rely on independent healthcare valuation practices such as VMG Health, whose published thought leadership sits at vmghealth.com/insights.
8. Named boutique advisory coverage of the imaging vertical is thin; the two most commonly referenced practitioner-facing firms would be Provident Healthcare Partners and Cain Brothers, a division of KeyBanc Capital Markets.
9. Owner-radiologist rollover equity, typically 15% to 35% in PE-backed transactions per practitioner commentary in Becker’s, would drive after-tax proceeds more than the headline multiple.
10. PACS/RIS integration risk would materially affect the earnout and holdback structure in any imaging MSO transaction and belongs in the letter of intent, not in Day 100 planning.

Radiology practice multiples by size band

Radiology multiples are not publicly disclosed for private MSO transactions. Any table below should be read as illustrative practitioner-commentary bands, not an appraisal. The specific multiple a given practice would clear depends on modality mix, contract concentration, PE platform capacity, geography, and rollover terms. Size band (Adjusted EBITDA) Typical buyer type Illustrative multiple band (conditional) Structural note Under $1M Regional roll-in, tuck-in to existing platform Would range narrowly, typically low.

Radiology multiples are not publicly disclosed for private MSO transactions. Any table below should be read as illustrative practitioner-commentary bands, not an appraisal. The specific multiple a given practice would clear depends on modality mix, contract concentration, PE platform capacity, geography, and rollover terms.

Size band (Adjusted EBITDA)	Typical buyer type	Illustrative multiple band (conditional)	Structural note
Under $1M	Regional roll-in, tuck-in to existing platform	Would range narrowly, typically low single digits	Often asset-purchase, seller-financed component common
$1M to $3M	Sub-platform for PE MSO, regional strategic	Would range in the mid single-digit band per practitioner commentary in Becker’s imaging coverage	MSO structure required in CPOM states
$3M to $10M	Platform add-on for national PE MSO	Would range meaningfully higher than sub-$3M per PitchBook healthcare services commentary	Rollover equity 15% to 35% typical
$10M+	Standalone platform, potential public strategic (RadNet) interest	Would command a premium band; specific multiples not publicly disclosed	Multi-hospital PSA book and subspecialty depth drive the top end

What moves the multiple in a radiology M&A transaction

The 12 drivers below would be modeled by any specialist buyer’s diligence team, ranked roughly by the frequency they appear in radiology transaction commentary published by the American College of Radiology , Becker’s Hospital Review , and independent healthcare valuation practices such as VMG Health .

The 12 drivers below would be modeled by any specialist buyer’s diligence team, ranked roughly by the frequency they appear in radiology transaction commentary published by the American College of Radiology, Becker’s Hospital Review, and independent healthcare valuation practices such as VMG Health.

1. Hospital contract concentration. A single PSA above 40% of revenue would compress the multiple; a diversified book of three to five PSAs plus outpatient imaging centers would expand it.
2. Modality mix. Advanced imaging (MRI, PET/CT, interventional, women’s imaging) carries higher professional-component reimbursement per the CMS Physician Fee Schedule and higher multiples in buyer models.
3. Teleradiology capability. Existing night and subspecialty read infrastructure would be a value-driver against comparators such as vRad.
4. Subspecialty depth. Neuro, breast, MSK, IR, and pediatric subspecialists would each carry premium rates and reduce hospital churn risk.
5. Payor mix. Commercial-heavy books outperform Medicare-heavy books because CMS imaging cuts, tracked in the Federal Register CMS docket, compress professional-component margin.
6. Radiologist retention. Employment agreements with non-competes conforming to state law and post-close comp structures would be pre-negotiated before signing.
7. PACS/RIS platform. A modern, integrable PACS would reduce post-close integration cost; a legacy on-premise PACS would drive earnout structure.
8. Same-store revenue growth. Trailing 3-year same-store growth would be modeled, with weather-adjusted volume commentary in the CIM.
9. Outpatient imaging center ownership. Owned outpatient centers with real estate would command a separate cap-rate analysis alongside the operating multiple.
10. Rollover equity structure. The percentage rolled and the strike on the MSO equity would drive after-tax proceeds more than headline enterprise value.
11. Physician age curve. A group where the top three RVU generators are within five years of retirement would face a mandatory succession discount.
12. Regulatory posture. Compliance history under the HHS Office of Inspector General anti-kickback and Stark rules would be reviewed line by line in QoE.

Active buyers in radiology M&A

The named-platform universe below reflects public disclosures and reported PE sponsorship as of the most recent filings and press coverage. Radiology M&A remains dominated by a small number of PE-backed MSO consolidators plus one primarily public strategic.

The named-platform universe below reflects public disclosures and reported PE sponsorship as of the most recent filings and press coverage. Radiology M&A remains dominated by a small number of PE-backed MSO consolidators plus one primarily public strategic.

Radiology Partners

Radiology Partners is the largest PE-backed physician-led radiology practice in the United States, backed by New Enterprise Associates and other institutional investors per company disclosures. The platform’s teleradiology division would compete directly with vRad on subspecialty and night reads, and its practice-integration playbook is well known to radiology sellers.

RadNet, Inc.

RadNet, Inc. (NASDAQ: RDNT) is the largest publicly traded outpatient imaging operator, with financial disclosures accessible via RadNet investor relations and quarterly filings at SEC EDGAR. RadNet’s growth has been center-focused rather than PSA-focused, so groups selling primarily outpatient imaging centers would have a natural strategic bid.

LucidHealth

LucidHealth is backed by Excellere Partners per Excellere’s disclosed portfolio, and has grown through Midwest-anchored radiology practice affiliations.

US Radiology Specialists

US Radiology Specialists is backed by Welsh, Carson, Anderson & Stowe, per Welsh Carson’s disclosed healthcare portfolio at welshcarson.com/portfolio. The platform has expanded across multiple states via practice affiliation.

Envision Radiology

Envision Radiology is a private group operating outpatient imaging centers across multiple states.

Hospital systems and academic centers

Hospital and health-system employment continues to be a live alternative for radiology groups holding a dominant PSA. The American Hospital Association tracks health-system employment trends, and hospital insourcing of outpatient imaging would remain a strategic option in 2026.

The boutique M&A advisors who specialize in radiology

Boutique advisory coverage of the imaging vertical is thin relative to dermatology, veterinary, or MSSP, where multiple named specialist banks compete on every deal. The advisors named below appear in radiology and broader physician-services transaction commentary, and each is described neutrally with a citation link.

Boutique advisory coverage of the imaging vertical is thin relative to dermatology, veterinary, or MSSP, where multiple named specialist banks compete on every deal. The advisors named below appear in radiology and broader physician-services transaction commentary, and each is described neutrally with a citation link.

Provident Healthcare Partners

Provident Healthcare Partners is a healthcare-focused M&A advisory firm with a physician-services practice covering multiple specialties, including imaging. Provident’s published sector commentary is available at providenthp.com/insights.

Cain Brothers, a division of KeyBanc Capital Markets

Cain Brothers is a healthcare-dedicated investment bank operating as a division of KeyBanc Capital Markets and covering healthcare services including physician services and imaging. Cain Brothers publishes healthcare sector commentary at cainbrothers.com/insights.

Specialty M&A firms active in the radiology space

Additional specialty M&A firms active in the physician-services and imaging space would surface in seller processes on a deal-by-deal basis. Any advisor pitching a radiology mandate should be able to name (a) two or more radiology-specific transactions in the last 24 months and (b) named partner-level relationships at the PE-backed MSO platforms listed above.

Independent valuation practices

VMG Health, an independent healthcare valuation firm, publishes valuation methodology and market commentary at vmghealth.com/insights. VMG is commonly retained by hospitals, MSOs, and physician groups for fair-market-value opinions in transactions and PSA compensation reviews.

Where CT Acquisitions fits

CT Acquisitions is another lower-middle-market option specializing in the $1M to $50M enterprise-value band, positioned on owner-aligned fees and a vetted institutional buyer network . CT does not claim to be the largest radiology-focused advisor. For a large multi-hospital-PSA radiology platform above $10M of EBITDA, a full-scope healthcare bank such as Cain Brothers or a large healthcare boutique such as Provident would run a fuller institutional process. CT’s wedge is.

CT Acquisitions is another lower-middle-market option specializing in the $1M to $50M enterprise-value band, positioned on owner-aligned fees and a vetted institutional buyer network. CT does not claim to be the largest radiology-focused advisor. For a large multi-hospital-PSA radiology platform above $10M of EBITDA, a full-scope healthcare bank such as Cain Brothers or a large healthcare boutique such as Provident would run a fuller institutional process. CT’s wedge is the lower-middle-market band where a single-office or two-office outpatient imaging group, a small subspecialty radiology practice, or a founder-led teleradiology business needs a real sell-side process, not a broker listing, and where fee alignment on a smaller enterprise value matters more than a league-table logo. Practice owners weighing options can compare CT’s approach with a business broker or review the broader 2026 M&A advisor fee benchmark.

How the sell-side process works for a radiology practice

The engagement timeline below reflects a typical 8-to-12-month sell-side process for a radiology practice in the $2M to $15M adjusted EBITDA band. Larger platforms would extend timelines; a single-hospital exclusive PSA group would compress them.

The engagement timeline below reflects a typical 8-to-12-month sell-side process for a radiology practice in the $2M to $15M adjusted EBITDA band. Larger platforms would extend timelines; a single-hospital exclusive PSA group would compress them.

Month 1: Engagement and preparation

Advisor engagement, kickoff data request, and initial normalized-EBITDA build. Radiology-specific normalization would strip out one-time PSA true-ups, non-recurring capex on imaging equipment, and non-market physician compensation.

Months 2-3: Quality of Earnings and CIM

A radiology-specific Quality of Earnings analysis would model modality mix, payor mix, professional versus technical component revenue, and PSA renewal risk. The confidential information memorandum would present modality-weighted revenue, subspecialty coverage, teleradiology infrastructure, and hospital contract book.

Months 3-4: Buyer outreach

Targeted outreach would prioritize the PE-backed MSO platforms named above, RadNet’s outpatient center M&A team, and a curated list of regional strategics. Broad-market outreach is uncommon in radiology because the buyer universe is small and known.

Months 4-6: Management meetings and indications of interest

Initial indications of interest, followed by management meetings with 4-8 shortlisted buyers. Bidder-question focus in radiology would center on radiologist retention terms, PSA renewal cadence, and PACS/RIS integration.

Months 6-7: Letter of intent

Advisor-led LOI negotiation on price, rollover, escrow, earnout, and radiologist employment terms. Standard letter-of-intent economics reference points are available in the CT seller letter-of-intent guide.

Months 7-10: Confirmatory diligence

Legal, financial, regulatory, and IT diligence, including HHS OIG compliance review, Stark and anti-kickback review, PSA-by-PSA review, and PACS/RIS integration planning. Compliance findings would drive holdback structure.

Months 10-12: Signing, closing, and Day 1

Definitive agreement, regulatory notices, employment agreement execution, and Day 1 integration. A radiology due-diligence checklist would be updated at each stage.

Regulatory and structural mechanics for radiology M&A in 2026

CMS Physician Fee Schedule imaging cuts

The Medicare Physician Fee Schedule continues to reduce conversion-factor and code-specific reimbursement for imaging services, with cycle-by-cycle changes tracked in the Federal Register CMS docket and analyzed in advocacy briefs from the American College of Radiology. Any buyer model would sensitize adjusted EBITDA against a further 2% to 4% annual professional-component compression.

No Surprises Act

The federal No Surprises Act continues to shape out-of-network billing for hospital-based radiology contracts. Groups with meaningful out-of-network exposure at hospital facilities would need arbitration history and payor-relationship documentation ready for buyer diligence.

Corporate practice of medicine

State CPOM rules dictate whether a professional corporation can be sold directly to a corporate buyer or whether an MSO structure is required, per the American Medical Association CPOM overview. States including California, New York, Texas, and New Jersey have material CPOM restrictions; the required MSO structure would be locked in during engagement, not at signing.

Stark and anti-kickback

Physician self-referral (Stark) rules and the federal anti-kickback statute apply to imaging referral arrangements and hospital PSAs, enforced by the HHS Office of Inspector General. Compliance history would be diligenced line by line and reflected in the escrow.

FDA and equipment regulation

Imaging equipment sits under Food and Drug Administration oversight for device clearance and safety, with data at FDA Medical Devices. Buyers would review equipment age, service contracts, and any open FDA correspondence.

HIPAA and cybersecurity

PACS/RIS systems are covered under HIPAA, with breach reporting tracked publicly at the HHS Office for Civil Rights breach portal. Cybersecurity posture and prior breach history would be reviewed and priced.

State licensure and teleradiology

Teleradiology across state lines requires multi-state licensure and, in some states, participation in the Interstate Medical Licensure Compact. Buyers would model licensure logistics into integration planning.

How to choose an M&A advisor for a radiology practice

The 10-point checklist below distinguishes a radiology-competent advisor from a generalist broker. A seller who cannot get a specific answer to each question in an intake call would treat that as a negative signal. Named recent radiology or imaging transactions. Two or more in the last 24 months, ideally with the platforms named above. Partner-level relationships at named PE MSOs. Not associate-level, not “we can reach them.” Modality-weighted revenue modeling.

The 10-point checklist below distinguishes a radiology-competent advisor from a generalist broker. A seller who cannot get a specific answer to each question in an intake call would treat that as a negative signal.

1. Named recent radiology or imaging transactions. Two or more in the last 24 months, ideally with the platforms named above.
2. Partner-level relationships at named PE MSOs. Not associate-level, not “we can reach them.”
3. Modality-weighted revenue modeling. The advisor should show a sample CIM section, redacted, that models modality mix explicitly.
4. PSA-by-PSA diligence framework. Contract concentration analysis by hospital, not aggregate.
5. Teleradiology valuation experience. Understanding of vRad and Radiology Partners teleradiology as comparators.
6. State CPOM familiarity. Advisor should name the required MSO structure for the seller’s state without a lookup.
7. Rollover equity modeling. After-tax proceeds by rollover percentage, not just headline multiple.
8. Fee alignment. Success-fee structure and how it aligns with maximizing enterprise value; compare against the CT fee-structure guide.
9. Named Quality of Earnings partner. A pre-vetted radiology-experienced QoE firm ready to engage on Day 1.
10. Radiologist retention playbook. Employment agreement templates, non-compete review by state, and post-close comp modeling.

Frequently asked questions

What multiple would a radiology practice trade at in 2026?

Private radiology MSO transaction multiples are not publicly disclosed, so any specific range should be treated as practitioner commentary rather than a market quote. Practitioner commentary in Becker’s imaging coverage would suggest mid to high single-digit adjusted-EBITDA multiples for platform-scale practices, with sub-$1M EBITDA groups trading at meaningfully lower bands.

Who are the largest buyers of radiology practices?

The largest active buyers would be Radiology Partners, RadNet, Inc. (NASDAQ: RDNT), LucidHealth, US Radiology Specialists, and Envision Radiology, alongside hospital systems continuing to insource outpatient imaging.

How long does it take to sell a radiology practice?

A typical sell-side process would run 8 to 12 months from advisor engagement through close, with regulatory diligence, PSA review, and radiologist employment negotiation extending the back half of the timeline for larger platforms.

Do I need a healthcare specialist advisor, or will a generalist work?

A radiology-experienced advisor would materially outperform a generalist broker on the questions that drive value: modality-weighted revenue, PSA concentration, CPOM structure, teleradiology positioning, and rollover terms. A generalist would likely undervalue the group and mis-negotiate the LOI.

How much rollover equity is typical in a PE-backed radiology transaction?

Rollover equity of 15% to 35% would be typical in a PE-backed MSO deal, per practitioner commentary in Becker’s. The specific percentage and the strike on the MSO equity would drive after-tax proceeds materially.

How do CMS imaging cuts affect valuation?

CMS Physician Fee Schedule reductions to imaging codes, tracked in the Federal Register, would be sensitized in every buyer model. Groups with heavier commercial payor mix would carry less reimbursement risk than Medicare-heavy groups and would clear a higher multiple.

What happens to hospital PSAs in a sale?

Hospital professional services agreements would be reviewed line by line in diligence, with concentration above 40% of revenue treated as a valuation compressor. Renewal timing, exclusivity, and change-of-control provisions in each PSA would drive escrow and earnout terms.

What are the alternatives to a PE-backed MSO sale?

Alternatives would include a strategic sale to RadNet for outpatient-center-heavy groups, hospital-system employment for PSA-dominant groups, or a partial-recap where owners retain majority equity and bring in a minority PE partner.

Related CT resources

Practice owners preparing for a sale would commonly review the CT M&A advisory overview, and, for benchmarking against other physician-services verticals, the CT M&A advisor for dental practice and CT M&A advisor for veterinary practice guides. Fee benchmarking sits in the 2026 M&A advisor fees guide. Owners weighing PE versus family-office buyers would review the family office vs PE buyer comparison.

Methodology and data sources

This guide draws on public disclosures and regulatory materials from the Centers for Medicare and Medicaid Services , the Federal Register CMS docket , the American College of Radiology , the American Medical Association , SEC EDGAR filings (including RadNet, Inc.

This guide draws on public disclosures and regulatory materials from the Centers for Medicare and Medicaid Services, the Federal Register CMS docket, the American College of Radiology, the American Medical Association, SEC EDGAR filings (including RadNet, Inc. filings), the HHS Office of Inspector General, the HHS Office for Civil Rights, the FDA Medical Devices center, published sector commentary from Becker’s Hospital Review imaging, PE portfolio disclosures from New Enterprise Associates, Excellere Partners, and Welsh, Carson, Anderson & Stowe, valuation methodology commentary from VMG Health, advisory practice commentary from Provident Healthcare Partners and Cain Brothers, and platform disclosures from Radiology Partners, RadNet, Inc., LucidHealth, US Radiology Specialists, Envision Radiology, and vRad. Interstate licensure references draw on the Interstate Medical Licensure Compact.

Multiples ranges cited are practitioner commentary bands, not appraisals. Radiology MSO transactions are private and specific multiples are not publicly disclosed. All private-company references use conditional tense because no third party can verify a specific private transaction multiple without direct data-room access. Named PE platforms and their portfolio companies reflect public sponsor disclosures as of the last review date; sponsor relationships change and readers should verify current sponsorship at the sponsor’s website before citing.

Disclaimer: This guide is not an appraisal, not investment advice, not legal advice, not tax advice, not financial advice, and not a prediction. Practice owners considering a sale should engage a qualified M&A advisor, a healthcare attorney familiar with their state’s CPOM regime, and independent tax counsel. Every private transaction is negotiated on its own facts and no range published here can substitute for a data-room-based bid.